NCT02431260 - An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 14, 2015

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions

Solid Tumors and Hematologic Malignancy

Interventions

DRUG

INCB054329 Monotherapy

Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the treatment group A (TGA), with subsequent cohort escalations in the three treatment groups (TGA, TGB, and TGC) based on protocol-specific criteria

Trial Locations (12)

47905

Horizon Oncology Center, Lafayette

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

60611

Northwestern Memorial Hospital, Chicago

60637

The University of Chicago Medical Center, Chicago

63110

Washington University School of Medicine in St. Louis, St Louis

77030

The University of Texas MD Anderson Cancer Center, Houston

80218

Sarah Cannon Research Institute Research Center, Denver

90048

Cedars-Sinai Medical Center, Los Angeles

94115

University of California, San Francisco, Medical Center at Mount Zion, San Francisco

98109

Seattle Cancer Care Alliance, Seattle

21287-0013

John Hopkins, Baltimore

37232-0021

Vanderbilt University Medical Center, Nashville